A Phase I Study of Triapine(®) in Combination with Doxorubicin in Patients with Advanced Solid Tumors

PURPOSE: To assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics and antitumor activity of Triapine(®) administered in combination with doxorubicin. STUDY DESIGN: Patients were treated with doxorubicin intravenously (IV) on day 1 and Triapine(®) IV on days 1-4 of a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Schelman, William R., Morgan-Meadows, Sherry, Marnocha, Rebecca, Lee, Fred, Eickhoff, Jens, Huang, Wei, Pomplun, Marcia, Jiang, Zhisheng, Alberti, Dona, Kolesar, Jill M., Ivy, Percy, Wilding, George, Traynor, Anne M.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2008
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3050713/
https://ncbi.nlm.nih.gov/pubmed/19082825
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-008-0890-8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares